News

Nanobodies are a new class of therapeutic proteins that contain the unique structural and functional properties of naturally occurring single domain antibodies. The partners will collaborate to research

Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with recombinant human C1 inhibitor (rhC1INH) under an investigator IND from the FDA. Recombinant human

In turn, this will permit the expansion of Interleukin Genetics’s distribution network for such genetic tests. Under the agreement, Access Business Group’s existing license to the Interleukin Genetics’s

Data from the study demonstrate that the 100mg/day cohort achieved a mean plasma viral load reduction of 1.87 log10 after seven days of treatment, similar to the potency

Proceeds from the financing will be used to fund near-term product launches, product development activities and strategic business initiatives. Jeffrey Yordon, CEO, founder and chairman of the board

The Invitrogen technology covered in these agreements involves methods and kits for substantially amplifying nucleic acids. It is reported to be useful in several common laboratory techniques, including

The Crooke patent estate is a family of patents stemming from the research of Stanley Crooke and others at Isis to identify and design RNA molecules that harness

Priority review is granted to applications for products that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of

These funds are part of a five-year grant totaling $1.9 million that the National Institutes of Health (NIH) awarded the company in September 2006 to study the underlying